BACKGROUND: In patients with relapsed ovarian cancer, the objectives of salvage therapy are considered to be maintenance of quality of life and prolongation of patient survival. Chemotherapy using oral agents could be a good choice for salvage therapy. We reassessed the usefulness of oral cyclophosphamide (CPA) salvage therapy for heavily pretreated patients with recurrent epithelial ovarian cancer. METHODS: We evaluated the effects and toxicities of 100 mg oral dose (50 mg twice a day) of CPA for 14 patients who had undergone an average of 3 chemotherapy treatments before enrolling in our study. RESULTS: One patient showed partial response and 8 developed stable diseases. Median time to progression was 3 months (range 1-13 months) and median survival was 7 months (range 2-28 months). Common Terminology Criteria for Adverse Events (CTCAE) grade 3/4 adverse effects were leukopenia (7.1%), neutropenia (14.3%), thrombocytopenia (7.1%), and nausea/vomiting (21.4%). CONCLUSION: Although moderate gastrointestinal toxicity was observed, oral CPA therapy contributed to improving the survival of heavily pretreated patients with recurrent epithelial ovarian cancer. A well-designed phase II trial in this regard is awaited.
BACKGROUND: In patients with relapsed ovarian cancer, the objectives of salvage therapy are considered to be maintenance of quality of life and prolongation of patient survival. Chemotherapy using oral agents could be a good choice for salvage therapy. We reassessed the usefulness of oral cyclophosphamide (CPA) salvage therapy for heavily pretreated patients with recurrent epithelial ovarian cancer. METHODS: We evaluated the effects and toxicities of 100 mg oral dose (50 mg twice a day) of CPA for 14 patients who had undergone an average of 3 chemotherapy treatments before enrolling in our study. RESULTS: One patient showed partial response and 8 developed stable diseases. Median time to progression was 3 months (range 1-13 months) and median survival was 7 months (range 2-28 months). Common Terminology Criteria for Adverse Events (CTCAE) grade 3/4 adverse effects were leukopenia (7.1%), neutropenia (14.3%), thrombocytopenia (7.1%), and nausea/vomiting (21.4%). CONCLUSION: Although moderate gastrointestinal toxicity was observed, oral CPA therapy contributed to improving the survival of heavily pretreated patients with recurrent epithelial ovarian cancer. A well-designed phase II trial in this regard is awaited.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A J González-Martín; E Calvo; I Bover; M J Rubio; A Arcusa; A Casado; B Ojeda; C Balañá; E Martínez; A Herrero; B Pardo; E Adrover; J Rifá; M J Godes; A Moyano; A Cervantes Journal: Ann Oncol Date: 2005-04-07 Impact factor: 32.976
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Jalid Sehouli; Dirk Stengel; Guelten Oskay-Oezcelik; Alain G Zeimet; Harald Sommer; Peter Klare; Martina Stauch; Axel Paulenz; Oumar Camara; Elke Keil; Werner Lichtenegger Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: David G Mutch; Mauro Orlando; Tiana Goss; Michael G Teneriello; Alan N Gordon; Scott D McMeekin; Yanping Wang; Dennis R Scribner; Martin Marciniack; R Wendel Naumann; Angeles Alvarez Secord Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544
Authors: M T Seymour; J L Mansi; C J Gallagher; M E Gore; P G Harper; T R Evans; P M Edmonds; M L Slevin Journal: Br J Cancer Date: 1994-01 Impact factor: 7.640
Authors: Rohan Gupta; Mihaela Cristea; Paul Frankel; Christopher Ruel; Chen Chen; Yingyu Wang; Robert Morgan; Lucille Leong; Warren Chow; Marianna Koczywas; Steve Koehler; Dean Lim; Thehang Luu; Cynthia Martel; Mark McNamara; George Somlo; Przemyslaw Twardowski; Yun Yen; Amanam Idorenyi; Tinsley Raechelle; Mary Carroll; Vincent Chung Journal: Cancer Treat Res Commun Date: 2019-07-03